Comparing Bispecific Antibody Format Feasibility

Not every antibody can be combined to produce well-behaved multi-specifics. The valency and geometry of each design can determine the production, target engagement and ultimately the requisite biological functions. In this case study, we selected two established antibody therapeutics, trastuzumab and a humanized OKT3 to produce 17 different bispecific formats to compare the feasibility of each format.
About the Speaker:
Ed Horton is the Chief Commercial Officer at Absolute Antibody. He is responsible for the commercial sales, marketing, and distribution networks in support of all business portfolios and constituents across the company. Previously, Ed has held the positions of Director of Sales, Marketing and Applications at Danaher-owned operating companies, including Beckman Coulter Life Sciences, Sciex and most recently as Sr. Director of North American Sales at Leica Biosystems from 2017-2021. He holds a B.S. Degree in Biochemistry and Genetics from Texas A&M University and his PhD in Chemistry.